key: cord-0924740-0y981qoq
authors: Kaul, Risheek; Sreenivasan, Jayakumar; Goel, Akshay; Malik, Aaqib; Bandyopadhyay, Dhrubajyoti; Jin, Chengyue; Sharma, Mala; Levine, Avi; Pan, Stephen; Fuisz, Anthon; Cooper, Howard A.; Panza, Julio A.
title: Myocarditis following COVID-19 vaccination
date: 2021-09-20
journal: Int J Cardiol Heart Vasc
DOI: 10.1016/j.ijcha.2021.100872
sha: fed3894c929714fb7fe34809f0554755913c01c7
doc_id: 924740
cord_uid: 0y981qoq

nan

The messenger ribonucleic acid (mRNA) -based BNT162b2 (Pfizer, Inc) and mRNA-1273 vaccines (Moderna, Inc) were demonstrated in large randomized clinical trials to be highly effective in preventing severe illness from COVID-19 and to have acceptable safety profiles [1, 2] . Given the short timeline between development and widespread utilization of this novel vaccine technology, however, careful investigation of possible unexpected adverse effects during real-world use is essential. In this report, we describe 2 cases of myocardial inflammation temporally associated with receipt of a COVID-19 mRNA vaccine in patients without evidence of concurrent or prior COVID-19 infection.

We describe 2 patients with acute myocarditis occurring within 72 hours after the administration of mRNA-based COVID-19 vaccine. Clinical presentations, in-hospital events, treatments, and outcomes are presented in the Table. Cardiac magnetic resonance imaging findings and electrocardiograms of both patients with myocarditis are shown in Figure 1 . Both patients were young males without significant medical history, and presented 2-3 days after receiving the second vaccine dose. No patient had a history of prior or current COVID-19 infection, and all had negative RT-PCR nasopharyngeal swab testing for COVID-19 during their hospital course.

With prompt recognition and treatment, all patients recovered quickly and were discharged from the hospital. The second patient followed up at 3 months after discharge and was completely asymptomatic without any other side effects.

This case series contributes to a limited body of literature describing acute myocardial and/or pericardial inflammatory illness occurring in close temporal association with the receipt of a mRNA COVID-19 vaccine. The possibility of a connection between COVID-19 vaccination and cardiac inflammatory illness was first suggested by a prelimary report from the the Israeli Health Ministry [3] which described a small number of cases of myopericarditis among young adults after receiving the BNT162b2 vaccine. Subsequently, 3 other case reports [4] [5] [6] and 3 case series [7] [8] [9] reporting myocarditis following COVID-19 vaccination have been published. Consistent with those recent reports, in our series all affected patients were males, and their illness was characterized by an uncomplicated hospital course and uneventful recovery with conventional treatment for myopericarditis.

In the published randomized clinical trials of these two COVID-19 mRNA vaccines, cardiovascular adverse events were exceedingly rare. Those that were reported included paroxysmal ventricular arrhythmias, arteriosclerosis and cardiac arrest, but there were no occurrences of myocarditis or pericarditis [1, 2] . Myopericarditis has been reported in association with other vaccines, and the temporal relationship between the onset of symptoms and administration of the vaccine in our patients would suggest a possible causal association.

Although mehanisms such as molecular mimicry between the viral spike protein and a cardiac protein or alternatively aberrant activation of the innate and acquired immune system leading to a non-specific inflammatory response have been suggested these potential mechanisms remain speculative.

It is important to consider these case reports within the broader context of the COVID-19 pandemic and the worldwide vaccination effort. COVID-19 has caused tremendous morbidity and mortality throughout the world, and the rapid development of safe and effective vaccines has provided hope that the pandemic can eventually be brought under control. Out of the more than 142 million Americans that have been vaccinated, fewer than 1000 cases of potential vaccineassociated myocarditis or pericarditis have been reported to Vaccine Adverse Event Reporting

Advisory Committee on Immunization Practices (ACIP) is ongoing [10] . Even if a causal relationship between mRNA COVID-19 vaccination and myopericarditis is established, the incidence appears to be extremely low, the outcomes seem to be favorable, and the benefit of vaccination far outweighs any potential risk.

We report 2 cases of myocarditis occurring in close temporal relation to receipt of an mRNA CMR -cardiac magnetic resonance imaging

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Israel examining heart inflammation cases in people who received Pfizer COVID shot | Reuters

Miocarditis aguda tras administración de vacuna BNT162b2 contra la COVID-19

In Depth Evaluation of a Case of Presumed Myocarditis Following the Second Dose of COVID-19 mRNA Vaccine

Myocarditis following COVID-19 vaccination

Myocarditis after BNT162b2 and mRNA-1273 Vaccination

Myocarditis Temporally Associated with COVID-19 Vaccination

Temporal relation between second dose BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection

CDC investigating rare myocarditis in teens, young adults; COVID-19 vaccine still advised for all who are eligible